person · Reporting owner

Szyman Catherine M.

Disclosed activity across 4 companies

Tapewire entity: 39015
SEC CIK: 0001438538

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Edwards Lifesciences CorpEW · Entity 3026	CVP, Critical Care	September 03, 2024	September 03, 2024
Outset Medical, Inc.OM · Entity 7026	Director	May 31, 2023	May 31, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Edwards Lifesciences Corp

Report date September 03, 2024 · Filed September 03, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	81,287.4373	Ending reported balance After 2024-09-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-09-03 · Grant · Acquired 10,910 · Balance 86,817.4373 F1: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date. Row 2 · 2024-09-03 · Tax withholding · Disposed 5,530 · Balance 81,287.4373

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date.

Outset Medical, Inc.

Report date May 31, 2023 · Filed May 31, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	24,596	Reported balance After 2023-05-31 transaction · row 1 1 source row Row 1 · 2023-05-31 · Grant · Acquired 7,681 · Balance 24,596 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Inari Medical, Inc.

Report date February 19, 2025 · Filed February 19, 2025

Section 16 reporting ended · disclosed 2025-02-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-02-19 transaction · row 1 1 source row Row 1 · 2025-02-19 · Other · Disposed 22,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.73	Direct	0	Reported balance After 2025-02-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-19 · Disposition to issuer · Disposed 49,719 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.

F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

MASIMO CORP

Report date June 10, 2026 · Filed June 12, 2026

Section 16 reporting ended · disclosed 2026-06-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Disposition to issuer · Disposed 7,605 · Balance 0 F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Disposition to issuer · Disposed 22,283 · Balance 0 F4: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-06-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-10 · Disposition to issuer · Disposed 6,306 · Balance 0 F5: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-06-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-10 · Disposition to issuer · Disposed 39,904 · Balance 0 F6: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $166.52	Direct	Reported balance After 2026-06-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-10 · Disposition to issuer · Disposed 18,617 · Balance 0 F7: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
Performance-Based Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-06-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-06-10 · Disposition to issuer · Disposed 49,243 · Balance 0 F9: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance. F8: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration").

F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33).

F4: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years.

F5: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years.

F6: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years.

F7: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding.

F8: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding.

F9: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 14, 2022 Filed Jan 15, 2022 00:16 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	8,884	$119.47	$1,061,328.84	Disclosure SEC source: 0001225208-22-000769 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,414.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $118.960 to $119.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 14, 2022 Filed Jan 15, 2022 00:16 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	1,116	$120.01	$133,934.40	Disclosure SEC source: 0001225208-22-000769 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,298.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $119.960 to $120.085. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 14, 2022 Filed Jan 15, 2022 00:16 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	10,000	$21.76	$217,600.00	Disclosure SEC source: 0001225208-22-000769 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,414.5223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. Read SEC document
December 17, 2021 Filed Dec 18, 2021 00:51 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	10,000	$0.00 Strike: $21.76	$0.00	Disclosure SEC source: 0001225208-21-015136 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,400 Underlying: Common Stock · 10,000 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2021 Filed Dec 18, 2021 00:51 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	10,000	$121.24	$1,212,400.00	Disclosure SEC source: 0001225208-21-015136 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,414.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. Read SEC document
December 17, 2021 Filed Dec 18, 2021 00:51 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	10,000	$21.76	$217,600.00	Disclosure SEC source: 0001225208-21-015136 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,414.5223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. Read SEC document
November 18, 2021 Filed Nov 19, 2021 22:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	10,000	$0.00 Strike: $21.76	$0.00	Disclosure SEC source: 0001225208-21-013981 · doc4.xml · derivative · entry 5 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,400 Underlying: Common Stock · 10,000 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 18, 2021 Filed Nov 19, 2021 22:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	6,357	$117.88	$749,394.31	Disclosure SEC source: 0001225208-21-013981 · doc4.xml · nonDerivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,414.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $117.5790 to $118.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 18, 2021 Filed Nov 19, 2021 22:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	2,390	$116.98	$279,586.26	Disclosure SEC source: 0001225208-21-013981 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,771.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $116.4900 to $117.3600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 18, 2021 Filed Nov 19, 2021 22:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	1,253	$118.87	$148,947.12	Disclosure SEC source: 0001225208-21-013981 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,161.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $118.5900 to $118.8800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 18, 2021 Filed Nov 19, 2021 22:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	10,000	$21.76	$217,600.00	Disclosure SEC source: 0001225208-21-013981 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,414.5223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. Read SEC document
October 18, 2021 Filed Oct 18, 2021 21:00 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	9,741	$0.00 Strike: $21.76	$0.00	Disclosure SEC source: 0001225208-21-013132 · doc4.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,400 Underlying: Common Stock · 9,741 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 18, 2021 Filed Oct 18, 2021 21:00 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	7,138	$110.24	$786,883.13	Disclosure SEC source: 0001225208-21-013132 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,414.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $109.6400 to $110.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
October 18, 2021 Filed Oct 18, 2021 21:00 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	2,603	$110.87	$288,598.51	Disclosure SEC source: 0001225208-21-013132 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,552.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $110.6400 to $110.9100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
October 18, 2021 Filed Oct 18, 2021 21:00 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	9,741	$21.76	$211,964.16	Disclosure SEC source: 0001225208-21-013132 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,155.5223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. Read SEC document
September 08, 2021 Filed Sep 9, 2021 01:04 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	9,741	$0.00 Strike: $21.76	$0.00	Disclosure SEC source: 0001225208-21-012145 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,141 Underlying: Common Stock · 9,741 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 08, 2021 Filed Sep 9, 2021 01:04 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	9,741	$121.28	$1,181,362.18	Disclosure SEC source: 0001225208-21-012145 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,414.5223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $120.9950 to $121.7000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
September 08, 2021 Filed Sep 9, 2021 01:04 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	9,741	$21.76	$211,964.16	Disclosure SEC source: 0001225208-21-012145 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,155.5223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. Read SEC document
August 05, 2021 Filed Aug 6, 2021 00:41 UTC	Edwards Lifesciences Corp EW · Entity 3026	GiftCommon Stock	344.3865	$0.00	$0.00	Disclosure SEC source: 0001225208-21-011248 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,414.5223 Read SEC document
August 02, 2021 Filed Aug 3, 2021 01:35 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	15,000	$0.00 Strike: $21.76	$0.00	Disclosure SEC source: 0001225208-21-011037 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,882 Underlying: Common Stock · 15,000 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 02, 2021 Filed Aug 3, 2021 01:35 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	15,000	$113.53	$1,702,903.50	Disclosure SEC source: 0001225208-21-011037 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,758.9088 F1 · price: This transaction was executed in multiple trades at prices ranging from $113.4450 to $113.7500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
August 02, 2021 Filed Aug 3, 2021 01:35 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	15,000	$21.76	$326,400.00	Disclosure SEC source: 0001225208-21-011037 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,758.9088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2021 Filed Jun 16, 2021 00:33 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	3,410	$0.00 Strike: $22.29	$0.00	Disclosure SEC source: 0001225208-21-009449 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,410 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2021 Filed Jun 16, 2021 00:33 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	3,410	$101.17	$344,989.70	Disclosure SEC source: 0001225208-21-009449 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,704.7936 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
June 15, 2021 Filed Jun 16, 2021 00:33 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	3,410	$22.29	$75,997.65	Disclosure SEC source: 0001225208-21-009449 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,114.7936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:13 UTC	Outset Medical, Inc. OM · Entity 7026	GrantCommon Stock	3,288	$0.00	$0.00	Disclosure SEC source: 0001484612-21-000016 · edgardoc.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,035 F1 · shares: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document
May 28, 2021 Filed May 28, 2021 23:38 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	2,061	$95.29	$196,392.69	Disclosure SEC source: 0001225208-21-008675 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,704.7936 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
May 27, 2021 Filed May 28, 2021 18:35 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	1,380	$0.00	$0.00	Disclosure SEC source: 0001562180-21-003841 · primarydocument.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,471 F1 · shares: Represents RSUs granted on May 27, 2021 to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2022 annual meeting. Read SEC document
May 25, 2021 Filed May 25, 2021 23:27 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	4,665.4212	$96.09	$448,300.32	Disclosure SEC source: 0001225208-21-008560 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,765.7936 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
May 20, 2021 Filed May 24, 2021 21:01 UTC	Outset Medical, Inc. OM · Entity 7026	GrantCommon Stock	5,747	$0.00	$0.00	Disclosure SEC source: 0001567619-21-011055 · doc1.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,747 F1 · shares: Represents restricted stock units ("RSU") granted to the reporting person on May 20, 2021. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest quarterly over three years, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document
May 17, 2021 Filed May 19, 2021 20:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionPerformance Rights · Derivative	15,225	$0.00	$0.00	Disclosure SEC source: 0001225208-21-008305 · doc4.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,225 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. Read SEC document
May 17, 2021 Filed May 19, 2021 20:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	7,549	$89.49	$675,560.01	Disclosure SEC source: 0001225208-21-008305 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,431.2148 Read SEC document
May 17, 2021 Filed May 19, 2021 20:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	1,729	$89.49	$154,728.21	Disclosure SEC source: 0001225208-21-008305 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,980.2148 Read SEC document
May 17, 2021 Filed May 19, 2021 20:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	15,225	$0.00	$0.00	Disclosure SEC source: 0001225208-21-008305 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,709.2148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. Read SEC document
May 11, 2021 Filed May 13, 2021 01:38 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	2,028	$90.40	$183,331.20	Disclosure SEC source: 0001225208-21-008061 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,484.2148 Read SEC document
May 07, 2021 Filed May 7, 2021 22:32 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	3,389	$0.00 Strike: $22.29	$0.00	Disclosure SEC source: 0001225208-21-007763 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,410 Underlying: Common Stock · 3,389 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 07, 2021 Filed May 7, 2021 22:32 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	3,389	$91.87	$311,347.43	Disclosure SEC source: 0001225208-21-007763 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,940.2148 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
May 07, 2021 Filed May 7, 2021 22:32 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	3,389	$22.29	$75,529.63	Disclosure SEC source: 0001225208-21-007763 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,329.2148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
May 07, 2021 Filed May 11, 2021 14:03 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	428	$91.75	$39,269.00	Disclosure SEC source: 0001225208-21-007901 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,901.2148 F1 · balance_after: Does not reflect transactions effected on May 7, 2021 pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020, which transactions were reported on a Form 4 filed with the SEC on May 7, 2021. The actual amount of securities beneficially owned by the Reporting Person following transaction reported on this Form 4 is 30,512.2148. Read SEC document
May 04, 2021 Filed May 7, 2021 01:10 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantPerformance Rights · Derivative	4,950	$0.00	$0.00	Disclosure SEC source: 0001225208-21-007705 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 Underlying: Common Stock · 4,950 shares Expires 2028-05-03 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document
May 04, 2021 Filed May 7, 2021 01:10 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantEmployee Stock Option (Right to Acquire) · Derivative	34,600	$0.00 Strike: $93.31	$0.00	Disclosure SEC source: 0001225208-21-007705 · doc4.xml · derivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,600 Underlying: Common Stock · 34,600 shares Expires 2028-05-03 F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document
May 04, 2021 Filed May 7, 2021 01:10 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantCommon Stock	3,975	$0.00	$0.00	Disclosure SEC source: 0001225208-21-007705 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,940.2148 F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document
April 22, 2021 Filed Apr 23, 2021 00:05 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	3,389	$0.00 Strike: $22.29	$0.00	Disclosure SEC source: 0001225208-21-006929 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,799 Underlying: Common Stock · 3,389 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 22, 2021 Filed Apr 23, 2021 00:05 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	3,389	$94.40	$319,921.60	Disclosure SEC source: 0001225208-21-006929 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,966.0572 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
April 22, 2021 Filed Apr 23, 2021 00:05 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	3,389	$22.29	$75,529.63	Disclosure SEC source: 0001225208-21-006929 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,355.0572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
March 15, 2021 Filed Mar 15, 2021 22:02 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	3,389	$0.00 Strike: $22.29	$0.00	Disclosure SEC source: 0001225208-21-005358 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,188 Underlying: Common Stock · 3,389 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 15, 2021 Filed Mar 15, 2021 22:02 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	3,389	$81.66	$276,745.74	Disclosure SEC source: 0001225208-21-005358 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,746.1397 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
March 15, 2021 Filed Mar 15, 2021 22:02 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	3,389	$22.29	$75,529.63	Disclosure SEC source: 0001225208-21-005358 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,135.1397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document
February 16, 2021 Filed Feb 17, 2021 00:40 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	3,389	$0.00 Strike: $22.29	$0.00	Disclosure SEC source: 0001225208-21-002568 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,577 Underlying: Common Stock · 3,389 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2021 Filed Feb 17, 2021 00:40 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	3,389	$88.20	$298,909.80	Disclosure SEC source: 0001225208-21-002568 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,746.1397 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.